Cancer immunotherapy with immune checkpoint inhibitors (ICI), including monoclonal antibodies targeting cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), programmed cell death protein 1 (PD-1) and its ligand (PD-L1), has revolutionized cancer treatment by enhancing immune responses against tumors [1]. This evidence concerns the gene CTLA4 and cancer.